Drug Discovery and Development Solutions for Leukemia

Our In Vitro Efficacy Testing Service accelerates leukemia drug discovery by providing robust, sensitive screening and characterization platforms. We utilize advanced cell-based and biochemical assays—including ATP, chemiluminescent, FRET, HTRF, and RNA assays—to evaluate compound efficacy, cytotoxicity, and mechanisms of action. Targeting key leukemia-related proteins and pathways such as Abl kinase, Cereblon, CDK9, DDR2, and XIAP, we deliver quantitative pharmacological parameters (IC-50, EC-50, MIC, Kd, pIC-50). Our comprehensive, reproducible methodologies enable rapid optimization of therapeutic candidates, supporting informed preclinical development and guiding the selection of promising leukemia treatments.

Alfa Cytology provides comprehensive Leukemia animal model development services, supporting pharmaceutical, biotech, and academic research. Utilizing immunocompetent and immunodeficient rodents, we offer chemically induced, genetic, and patient-derived xenograft models that closely mimic human Leukemia subtypes. Our end-to-end solutions include model customization, cell engraftment, disease monitoring, and advanced analytics such as flow cytometry, molecular profiling, and PK/PD assessments. Rigorous quality control ensures data integrity and reproducibility. By partnering with Alfa Cytology, clients gain access to scientifically validated models and expert-driven study design, accelerating preclinical discovery and the development of novel anti-leukemic therapies.

Our Leukemia PK/PD research service delivers comprehensive expertise in drug exposure-response analysis, supporting the development and optimization of anti-leukemic therapies. We offer diverse administration routes and extensive compartment analysis, including plasma, bone marrow, and key tissues, using advanced analytical techniques such as HPLC-MS and ELISA. Employing translationally relevant animal models, our studies generate robust ADME and concentration-effect data, enabling rational dose selection and therapeutic window determination. Our integrated approach ensures actionable insights for efficacy, safety, and individualized treatment strategies, providing academic, biotech, and pharmaceutical partners with a proven platform for rigorous, data-driven Leukemia drug development.

Alfa Cytology delivers comprehensive in vivo toxicity assessment services for leukemia drug candidates, encompassing acute, chronic, organ-specific, and systemic studies. Utilizing advanced animal models and state-of-the-art methodologies such as high-throughput hematology, digital pathology, and in vivo imaging, we ensure rigorous data quality and regulatory compliance. Our multidisciplinary approach integrates specialized techniques like flow cytometry and bone marrow cytology, providing detailed safety profiles tailored to hematologic malignancies. Through robust data collection and cross-functional collaboration, Alfa Cytology empowers researchers with actionable insights, supporting informed decision-making and accelerating the development of safe, effective leukemia therapeutics.

Alfa Cytology offers biomarker analysis services supporting leukemia research, utilizing advanced multi-omics platforms to explore the molecular landscape underlying disease mechanisms. We employ high-throughput screening and rigorous evaluation methodologies to investigate and assess candidates with potential as leukemia biomarkers. Our analytical capabilities encompass genomics, transcriptomics, proteomics, and epigenomics, enabling comprehensive assessment of DNA, RNA, protein, and metabolite profiles. Through adaptable assay development and stringent quality control, we provide objective, data-driven support for preclinical research. Our expertise facilitates the exploration and potential evaluation of biomarker targets, advancing knowledge in leukemia pathophysiology and therapeutic development.